Under acquisition by Merck KGaA, Darmstadt, Germany (via EMD Holdings NewCo, Inc.)
$73.00 per share in cash. This report does not carry a fundamental rating or price target. Price is set by the deal terms and by deal risk, not by discounted cash flow or multiples. The downside case here is DEAL BREAK, not a de-rating.
| Deal | |
|---|---|
| Acquirer | Merck KGaA, Darmstadt, Germany (via EMD Holdings NewCo, Inc.) |
| Consideration | $73.00 per share in cash |
| Spread to spot | +1.35% (spot $72.03) |
| Annualised to expected close | +2.67% over 185 days |
| Announced | 2026-06-25 |
| Expected close | 2027-01-31 |
| Principal risk | Deal break — not a de-rating |
| Source | Bio-Techne Form 8-K Item 1.01 accession 0001999371-26-013527 (tech-8k_062326.htm), $73.00 cash |
The engine's standalone valuation is retained internally (HOLD, $71.4) but is NOT the operative frame while the deal holds — a company being bought for cash does not trade on its own multiples. It becomes the operative view again if the deal terminates.
mature cash generator · conviction: medium
| Metric | Value |
|---|---|
| Current Price | $72.03 |
| Triangulated Fair Value | $65.16 (-10% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $72.72 (+1% vs spot · 12m PWEV) |
| Forward P/E | 35.3x |
| Market Cap | $11B |
| 52-Week Range | $43.12–$72.12 |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-07-29. Each chart below sits with the part of the thesis it evidences.
General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.
Investment Committee Summary
| Frame | Pending acquisition — $73.00 cash · no fundamental rating |
| Classification · conviction | mature cash generator · medium |
| Triangulated fair value | $65.16 (-10% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $72.72 (+1% vs spot · 12m PWEV) |
| Next catalyst | 2026-02-04 — FQ2 FY26 results + organic-growth and bioprocessing-recovery commentary |
| Primary thesis-break | Organic revenue growth (year-on-year) < 0.0 (2 consecutive prints) |
Decision detail — rating tables & Research OS strip
Decision Support — Research OS jump to detail ↓
| Conviction | Exp. return (1y) | Rules stance | Preferred options | Next catalyst |
|---|---|---|---|---|
| 66/100 (84th pct) | +1% 1yr expected | Hold | Long Stock | 2d — July nonfarm payrolls / unemployment |
Full breakdown — conviction components, position sizing, probability-return distribution, decision rules, factor & portfolio interaction, options intelligence and the catalyst timeline — in the Decision Support sections below. Model output for research; not individualised advice.
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Rating = HOLD because:
- Probability-weighted scenario value implies +1% vs spot
- Monte Carlo median implies -11% vs spot
- DCF fair value implies -16% vs spot — but this is terminal-value sensitive (exit-multiple $60.23 vs Gordon $38.04, 37% apart), so it carries less weight
- Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -59% vs spot
- Net: reward/risk of 0.2× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.
Investment Thesis
At roughly $71, on the engine's base earnings near $2.01 the stock trades close to a mid-thirties forward multiple. That price says the market expects biopharma R&D and bioprocessing demand to normalise to mid-single-digit organic growth without a durable margin reset, and it pays a quality-tools premium for that outcome. The engine takes a more balanced view. It anchors the base at +6% organic growth and a 30.4% operating margin, a 37x multiple, and cross-checks against a capex-light DCF near $62 and a peer-implied range in the mid-forties. Those anchors sit below spot, so the probability-weighted target lands near $71, essentially at the price, and the rating is HOLD rather than a directional call. The Monte Carlo carries about 40% probability above the current price, with the terminal multiple driving three-quarters of the variance. The single most damaging risk is the multiple: at a mid-thirties forward P/E against mid-single-digit growth, a de-rate toward peers on any China or bioprocessing disappointment compresses value faster than earnings recover.
The dashboard below is the whole argument on one page: spot ($72.03) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The highest-probability bear is the Reimbursement / Funding / Utilization Reset that the cluster puts near 37%. Its mechanism is concrete. Biopharma customers cut discovery and early-stage R&D budgets, bioprocessing destocking runs longer than a quarter or two, and China stays soft under funding and pricing pressure. Organic growth turns negative and holds there. On lower volume the 30.4% operating margin de-levers toward the high twenties because the tools base carries fixed cost. Earnings fall to the recession path near $1.60 while a mid-thirties multiple that assumed steady compounding de-rates toward the low thirties. Price and multiple then fall together, which is exactly how the Structural target below the 52-week low is built.
Key Debate
P/E Multiple explains 76% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
What the Market Is Pricing In
At the current price, the market pays 35.2× consensus forward EPS, vs the house DCF terminal 30.0×, and a peer median 22.625×. The house DCF sits 16% below spot, so the market is pricing in more than the house case — roughly 1.7pp of revenue CAGR.
Variant perception: the house view is in-line with consensus, and the thesis is primarily FCF-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 1.3 | 1.3 | High |
| EPS | 2.0 | 2.0 | Medium |
| Target price | 70.0 | 71.4 | Medium |
Scenario Analysis
The tree runs from a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($29.60) to a 'Bull — Re-Rate' bull case ($135); the probability-weighted blend (PWEV $72.72) is +1% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Biopharma-Funding / China / Bioprocessing Reset | 20% | $29.60 | -59% |
| R&D-Spend Recession | 17% | $51.10 | -29% |
| Base — Tools + Services Growth | 35% | $74.30 | +3% |
| Growth — Bioprocessing / Biologics Recovery | 20% | $106 | +48% |
| Bull — Re-Rate | 8% | $135 | +88% |
| Probability-Weighted (PWEV) | — | $72.72 | +1% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $29.60). Structural impairment — biopharma-funding / China / bioprocessing reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 31.42; probability: 0.2.
- R&D-Spend Recession (17%, $51.10). Cyclical downturn — biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding weakens for 1–2 years before normalising. Drivers — implied_target: 53.35; probability: 0.17.
- Base — Tools + Services Growth (35%, $74.30). Mid-cycle — normalised biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding; disciplined capital allocation; steady returns. Drivers — implied_target: 74.1; probability: 0.35.
- Growth — Bioprocessing / Biologics Recovery (20%, $106). Upside — bioprocessing + biologics recovery lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 100.03; probability: 0.2.
- Bull — Re-Rate (8%, $135). Upside tail — sustained tight conditions or a structural re-rate on bioprocessing + biologics recovery. Drivers — implied_target: 126.34; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $64.07 | -11% |
| Peer EV/Revenue re-rate | multiple | $43.32 | -40% |
| Scenario PWEV | multiple | $72.72 | +1% |
| DCF (5-year + terminal) | cash flow + terminal × | $60.23 | -16% |
| Triangulated (weighted) | — | $65.16 | -10% |
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $64.07 and 38% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (76% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 30x terminal FCF multiple → $60.23. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 22.625x) implies —. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 0% so the market's mood does not drive the fair value.
Across all anchors the spread is 46% of the median — wide (genuine disagreement — the blend carries low valuation confidence).
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 21.0x | 25.5x | 30.0x | 34.5x | 39.0x |
|---|---|---|---|---|---|
| 6% | $49.00 | $57.00 | $66.00 | $74.00 | $83.00 |
| 8% | $47.00 | $55.00 | $63.00 | $71.00 | $79.00 |
| 8% | $45.00 | $52.00 | $60.00 | $68.00 | $76.00 |
| 10% | $43.00 | $50.00 | $58.00 | $65.00 | $72.00 |
| 10% | $41.00 | $48.00 | $55.00 | $62.00 | $69.00 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $47.00 | $50.00 | $52.00 | $55.00 | $57.00 |
| -1.5pp | $51.00 | $53.00 | $56.00 | $59.00 | $61.00 |
| +0.0pp | $54.00 | $57.00 | $60.00 | $63.00 | $66.00 |
| +1.5pp | $58.00 | $62.00 | $65.00 | $68.00 | $71.00 |
| +3.0pp | $63.00 | $66.00 | $69.00 | $72.00 | $76.00 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Revenue CAGR ±3pp | $52.00 | $69.00 | $17.00 |
| Terminal × ±15% | $52.00 | $68.00 | $15.00 |
| Op margin ±3pp | $54.00 | $66.00 | $11.00 |
| WACC ±1pp | $58.00 | $63.00 | $5.00 |
| Capex intensity ±15% | $59.00 | $62.00 | $3.00 |
Company lever — SoP/share vs Life-Science Tools & Services multiple (AI re-rating) (base 35x)
| Multiple | 24.5x | 29.8x | 35.0x | 40.2x | 45.5x |
|---|---|---|---|---|---|
| SoP/share | $56.00 | $69.00 | $81.00 | $93.00 | $105 |
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| TMO | 19.72× | 6% | 18% | segment | 50% |
| DHR | 22.88× | 6% | 23% | segment | 50% |
| A | 22.37× | 6% | 24% | segment | 50% |
| WAT | 25.58× | 6% | 3% | segment | 50% |
Quality-weighted forward P/E: 22.6× (simple median 22.625×). Direct peers count 100%, segment 50%, broad 25%.
Historical-range cross-check: 52-week range $43.12–$72.12, centre $55.80 (-23% vs spot); spot sits at the 100th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV | $65.16 (-10% vs spot · triangulated FV) |
| Downside to bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) | $29.60 (-59% vs spot · bear scenario) |
| Reward/risk ratio | 0.2× |
| Margin of safety (FV vs spot) | -11% |
| P(price > spot) — Monte Carlo | 38% |
Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $135.
Company Overview & Business Model
Bio-Techne Corp — HEALTHCARE · BIOTECHNOLOGY. Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
How it makes money.
| Segment | Rev mix | Growth | Op margin | Key driver |
|---|---|---|---|---|
| Life-Science Tools & Services | 100% | +6% | 30% | biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical fu |
Edge. Wide moat — Bio-Techne's moat is real — spec'd-in reagents/antibodies and bioprocessing consumables with high switching costs (protocol validation, regulatory qualification) and razor-and-blade recurring revenue — which supports a premium tools multiple; but a ~35x+ forward multiple prices a durable growth reacceleration, so if organic growth stays stuck in low-single-digits the wide moat still cannot defend >30x and the terminal multiple should compress toward the tools-peer high-20s.
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Life-Science Tools & Services | $1.2B | 100% | 6% | 30% | $0.4B | 35x | 5% | ESTIMATE |
| EBIT = segment revenue × operating margin (segment EBITDA not shown — per-segment D&A is not separately disclosed). |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding |
| net_debt_or_cash_b | -0.08 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | 0.0054 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | biopharma-funding / China / bioprocessing reset |
| upside | bioprocessing + biologics recovery |
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $0.3B — modestly levered |
| Net debt / EBITDA | 0.77x |
| Interest coverage (EBIT / interest) | 11.9x |
| Current ratio | 3.45x |
| Lease obligations | $0.1B |
| Cash & ST investments | $0.2B |
Balance-sheet data as of 2025-06-30 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $0.3B |
| Buybacks / dividends | $0.3B / $0.1B |
| Total shareholder yield | 2.9% |
| Payout as % of FCF | 126.8% |
| Reinvestment (capex / OCF) | 10.8% |
| SBC as % of FCF | 16.0% |
| Allocation stance | returning more than FCF (balance-sheet funded) |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 21.4% |
| FCF conversion (FCF / net income) | 352.1% |
| FCF yield | 2.3% |
| Capex intensity (capex / revenue) | 2.6% |
| FCF − SBC (diagnostic) | $0.2B |
| Capex split (maint / growth) | 60% / 40% — Capital-light tools company (~4-5% of revenue): sustaining reagent/instrument facilities plus a meaningful growth slice for GMP bioprocessing capacity expansion, which is the margin-and-growth optionality. |
Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 394% — cash-backed.
Competitive Moat
Wide moat. Bio-Techne's moat is real — spec'd-in reagents/antibodies and bioprocessing consumables with high switching costs (protocol validation, regulatory qualification) and razor-and-blade recurring revenue — which supports a premium tools multiple; but a ~35x+ forward multiple prices a durable growth reacceleration, so if organic growth stays stuck in low-single-digits the wide moat still cannot defend >30x and the terminal multiple should compress toward the tools-peer high-20s.
Moat sources:
- FACT: proprietary antibody/reagent catalog spec'd into published protocols — switching means re-validating experiments
- FACT: consumables/reagents are recurring, high-gross-margin razor-and-blade revenue
- FACT: GMP bioprocessing (proteins/growth factors) qualified into customers' regulated manufacturing processes
- INFERENCE: moat is durable but growth-rate, not moat, is the debate — a wide moat at low growth still de-rates
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.43 vs analyst floor +0.19 → delta +0.24 (n=24 mgmt / 16 Q&A; 21th pctile across the S&P book, z -0.9).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.43 | +0.19 | +0.24 |
| 2026Q1 | +0.36 | +0.16 | +0.20 |
| 2025Q4 | +0.37 | +0.01 | +0.36 |
| 2025Q3 | +0.48 | +0.22 | +0.27 |
News (last 365d, 788 articles): avg ticker sentiment +0.16 (bullish 29% / bearish 7%)
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $70.00 (-3% vs spot · street) |
| House target | $71.40 (+2.0% vs street) |
| Sell-side coverage | 15 analysts (SB 1 / B 3 / H 11 / S 0 / SS 0; net score 0.17) |
| Consensus FY EPS | $2.05 (reference only — house values on EV/EBITDA) |
| Consensus FY revenue | $1.3B; house in-line (+2.8%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Catalyst Calendar
- 2026-02-04 (~-175d) — FQ2 FY26 results + organic-growth and bioprocessing-recovery commentary (authored)
- 2026-08-05 (~7d) — Quarterly earnings — est. EPS $0.46 (AV EARNINGS_CALENDAR)
- 2026-08-05 (~7d) — FY2026 full-year results (fiscal year ends late June) (authored)
- 2027-01-15 (~170d) — Biopharma-funding / biotech-IPO-and-venture-funding data update (authored)
Forecast Track Record
- EPS surprise: beat 62.5% of the last 8 quarters; average surprise +5.1%.
- Prior-forecast backtest (2 snapshots, 2026-06-27→2026-07-27): directional hit-rate 100.0%; mean predicted +1.1% vs realized +2.0%. Disconfirming track record is reported, not suppressed.
Catalyst Timeline
8 catalysts in the next 90 days (of 17 tracked). Importance 1–3; confidence 0–1.
| When | Catalyst | Type | Importance | Confidence |
|---|---|---|---|---|
| 2026-08-01 (in 2d) | July nonfarm payrolls / unemployment | macro | ●● | 0.8 |
| 2026-08-05 (in 6d) | Quarterly earnings | earnings | ●●● | 0.95 |
| 2026-08-05 (in 6d) | FY2026 full-year results (fiscal year ends late June) | authored | ● | 0.7 |
| 2026-08-12 (in 13d) | July CPI | macro | ●● | 0.8 |
| 2026-09-16 (in 48d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-09-18 (in 50d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2026-10-14 (in 76d) | September CPI | macro | ●● | 0.8 |
| 2026-10-28 (in 90d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2026-12-09 (in 132d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-12-18 (in 141d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-01-15 (in 169d) | Biopharma-funding / biotech-IPO-and-venture-funding data update | authored | ● | 0.7 |
| 2027-01-27 (in 181d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-03-17 (in 230d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-03-19 (in 232d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
_Sources: extended.catalysts, data/catalysts/
Regulatory & Legal Risk
| Issue | Probability | Valuation sensitivity | Horizon |
|---|---|---|---|
| US BIOSECURE-style China biotech restrictions and diagnostics/LDT (FDA) oversight | medium (~40%) | medium - China exposure and diagnostics unit at risk; ~5% of FV | 12-24m |
| NIH / academic research-funding budget cuts pressuring reagent demand | medium (~35%) | medium - academic/government is a real slice of reagent revenue; ~4% of FV | 12-24m |
Probabilities and sensitivities are analyst estimates, not market-implied.
Scenario Macro & Key Risks
| Scenario | Macro assumption | Key risk |
|---|---|---|
| Structural — Biopharma-Funding / China / Bioprocessing Reset | A durable reset in biopharma funding, China demand and bioprocessing destocking lowers the growth/margin base permanently. | The premium tools multiple de-rates on top of lower earnings, compounding downside. |
| R&D-Spend Recession | Broad biopharma and academic R&D-budget contraction cuts reagent and instrument demand. | Recurring-revenue framing overstates resilience if customers cut experiments outright. |
| Base — Tools + Services Growth | Biopharma R&D normalizes to mid-single-digit organic growth with a ~30% operating margin held. | Organic growth stalls in low-single-digits and the ~35x multiple cannot be sustained. |
| Growth — Bioprocessing / Biologics Recovery | Bioprocessing destock ends and biologics/cell-and-gene demand reaccelerates GMP-protein revenue. | Recovery timing slips and the bioprocessing inflection stays a year away for another year. |
| Bull — Re-Rate | A tools-sector re-rate on a funding recovery lifts the multiple back toward prior peak. | A re-rate ahead of proven reacceleration is fragile and reverses on a soft print. |
Decision Rules (Machine-Checked)
Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 5 evaluable (1 lacked data).
| Rule | Condition | Observed | Triggered |
|---|---|---|---|
| R1-valuation-stretch | expected return vs fair value < -12 (upside_pct) |
-0.87 | no |
| R2-valuation-opportunity | expected return vs fair value > 15 (upside_pct) |
-0.87 | no |
| R3-street-revisions | street net rating stance < -0.25 (extended.consensus.street_score) |
0.17 | no |
| R4-earnings-quality | cash conversion of earnings < 80 (extended.accounting_quality.cash_conversion_pct) |
394.5 | no |
| R5-technical-breakdown | price vs 200-day SMA < 0.85 (technicals.sma_200) |
1.41 | no |
| R6-vol-regime-shift | IV/RV vol-risk premium > 1.4 (options_overlay.iv_rv) |
no data | — |
Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- Organic revenue growth (year-on-year) < 0.0 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base assumes mid-single-digit organic growth of roughly six percent; sustained negative organic growth invalidates the mid-cycle demand path and moves weight to the R&D-Spend Recession scenario at minus five percent.
- Non-GAAP operating margin < 0.285 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base carries a 30.4% margin; a fall below the 28.5% base/recession midpoint signals volume de-leverage rather than a timing effect and erodes the earnings anchor.
- Bioprocessing / Protein Sciences segment growth < 0.0 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). The recovery and bull cases depend on bioprocessing reacceleration; a flat-to-declining bioprocessing line removes the mechanism that justifies any multiple above mid-cycle.
- China revenue growth (year-on-year) < -0.1 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). A double-digit China decline over two prints is a named structural risk and would pull weight toward the Structural reset scenario.
- FY forward non-GAAP EPS guidance < 1.8 (single event → Reimbursement / Funding / Utilization Reset). A guide below ~$1.80 falls short of the engine base EPS near $2.00 and prices closer to the recession path, challenging the HOLD.
Fact / Inference / Speculation
- FACT: Spot $72.03; 52-week range $43.12–$72.12; engine rating HOLD; house target $71.40 (-1%). (source: Alpha Vantage 2026-07-29, 30 July 2026)
- INFERENCE: Triangulated FV $65.16 (-10% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.
Balanced: triangulated fair value $65.16 (-10% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.
Conviction Score
66.1/100 (confidence band 55.3–76.8), 84th percentile of 854 covered names (as of 2026-07-30). Weighted composite under config ros-1.8.0 — every component and its inputs below.
| Component | Score (0–100) | Weight | Inputs |
|---|---|---|---|
| business quality | 87 | 15% | extended.fcf_quality.fcf_margin_pct, extended.balance_sheet.net_debt_to_ebitda, extended.accounting_quality.cash_conversion_pct |
| financial strength | 71 | 10% | extended.balance_sheet.net_debt_to_ebitda, extended.balance_sheet.interest_coverage |
| valuation | 49 | 15% | upside_pct |
| growth | 61 | 10% | reconciliation.ttm_revenue_billions, reconciliation.fy_guide_revenue_billions |
| earnings visibility | 62 | 10% | extended.forecast_accuracy.eps_surprise.beat_rate_pct |
| moat | 87 | 10% | enrichment.moat.rating |
| technical trend | 51 | 10% | technicals.rsi, technicals.sma_50, technicals.sma_200 |
| macro tailwinds | — | 10% | industry_context.house |
| risk profile | 58 | 10% | monte_carlo.prob_above_current, monte_carlo.p10, monte_carlo.p90, monte_carlo.median |
Missing inputs (macro_tailwinds) are excluded and the remaining weights renormalized; the confidence band widens accordingly.
Score history: 69.1 → 69.1 → 66.1 → 66.1 → 66.0 → 66.0.
Probability-Weighted Return Profile
Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.
| Scenario | Probability | Target | Total return | Contribution |
|---|---|---|---|---|
| Structural — Biopharma-Funding / China / Bioprocessing Reset | 20% | $29.60 | -58.9% | -11.8pp |
| R&D-Spend Recession | 17% | $51.10 | -29.1% | -4.9pp |
| Base — Tools + Services Growth | 35% | $74.30 | +3.2% | +1.1pp |
| Growth — Bioprocessing / Biologics Recovery | 20% | $106 | +47.9% | +9.6pp |
| Bull — Re-Rate | 8% | $135 | +87.6% | +7.0pp |
| Aggregate | Value |
|---|---|
| Expected return (gross, 1y) | +1.0% |
| Expected return net of SBC dilution | +1.0% |
| Outcome dispersion (σ, from MC p10–p90) | 34.0% |
| Expected Sharpe (rf 4%) | -0.09 |
| Downside expectation (prob-weighted loss branches) | -16.7% |
expected_return_pct is gross scenario math (reconciles to pwev_gross); expected_return_diluted_pct applies the SBC share-count dilution charge and matches the published PWEV-based target.
Expected Alpha
Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).
| Component | Value |
|---|---|
| Expected return (gross, 1y) | 1.0% |
| Risk-free rate | 4.13% (1y proxy (3m/2y midpoint; AV lacks a 1y tenor), as of 2026-07-27) |
| Beta (shrunk, 1y vs SPY) | 0.975 (as of 2026-07-28) |
| Equity risk premium | 4.5% |
| Required return | 8.5% |
| Expected alpha | -7.5% |
| Alpha per unit risk (EA/σ) | -0.22 |
A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.
Probability Cross-Checks
Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.
| Cross-check | Ours | Comparator | Reading |
|---|---|---|---|
| Mass above spot: scenarios vs our own MC | 63.0% | 37.5% | the scenario weights and the MC parameters disagree about our OWN view — this is a model-coherence issue, not a market disagreement |
| Realised scenario frequency | 6 dated anchors | — | only 6 dated anchors — below the 12 this check needs before it means anything. Reported so the absence is visible rather than looking like agreement. |
Authored set: 5 scenarios, probabilities summing to 1.0, mean target $72.72.
Flagged for review: internal_coherence. A flag marks a disagreement worth understanding — it does not imply either side is wrong.
Factor Exposures
Cross-sectional percentiles over 854 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.
| Style | Percentile | Theme | Percentile | |
|---|---|---|---|---|
| Growth | 92 | AI | 70 | |
| Value | 43 | Cloud | 79 | |
| Quality | 92 | Semis | 68 | |
| Momentum | 73 | Consumer | 69 | |
| Low-Vol | 2 | Rates | 80 | |
| USD | 19 | |||
| Energy | 52 |
Market interaction: correlation vs SPY +0.25, vs QQQ +0.19 (trailing ~1y daily returns).
Options Intelligence
Preferred structure: Long Stock. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.
- no directional edge and options are cheap — options add little; hold the stock
- Direction neutral from the overlay conviction/rating (read-only input).
- IV/RV at the 0th percentile of the cross-section (interim IV-rank proxy) → low vol bucket.
- No live-chain Long Stock was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.
No live-chain Long Stock was priced for this name — shown as the indicated approach; size against a fresh chain.
Alternatives: PMCC. IV rank via iv_rv_percentile_interim (interim). Model output for research and education only — not individualized investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.
Position Sizing Framework
under a pending acquisition — price is set by the deal terms and by deal risk, so the model carries no position.
| Parameter | Value |
|---|---|
| Initial position | 0.00% NAV |
| Maximum position | 0.00% NAV |
| Risk budget | 0.00% NAV |
| Annualized outcome σ (MC) | 34.0% |
| Indicative holding period | 3–12 months |
| Liquidity | high, ~$46M ADV (market-cap proxy (0.4%/day)) |
| Rebalancing trigger | position drifts ±25% from target weight, or the decision-rules stance changes |
Model output for research and education only — not individualized investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+2 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+3 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+4 | $1B | $0B | $0B | $0B | $0B | $0B |
| FY+5 | $2B | $1B | $0B | $0B | $0B | $0B |
| Terminal | — | — | — | — | $0B × 30x | $8B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $1B + PV(terminal) $8B = EV $10B; − net debt $0.1B → equity $10B ÷ diluted shares 0.16B = $60.23/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $38.04/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 35% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| TMO | 4.93x | 19.72x | 6% | 18% |
| DHR | 6.03x | 22.88x | 6% | 23% |
| A | 5.51x | 22.37x | 6% | 24% |
| WAT | 10.97x | 25.58x | 6% | 3% |
| Median | 5.77x | 22.625x | — | — |
Peer-median fwd P/E → —; EV/Rev → $43.32.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $60.23 | 47% | $28.11 |
| Scenario PWEV | $72.72 | 33% | $24.24 |
| Monte Carlo median | $64.07 | 20% | $12.81 |
| Triangulated | — | 100% | $65.16 |
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 8.5% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 30× | DCF exit value | estimate (peer-anchored) |
| Terminal growth | 2.5% | DCF Gordon terminal | estimate |
| SBC dilution | 0.0%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (17.0); Terminal × ±15% (15.0); Op margin ±3pp (11.0); WACC ±1pp (5.0); Capex intensity ±15% (3.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $1.2B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $1.3B | company guidance | Company guidance | Medium | Forecast, SoP |
| Consensus FY EPS | $2.0453 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.158B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $0.282B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 8.5% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 30× | house estimate | Peer/historical range | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | DCF Gordon terminal |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 30×, FY+5 revenue $2B. Triangulation leans 47% on DCF, 33% on PWEV.
Appendix & audit trail — source log, data provenance, disclosures
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-07-29 | Price, market cap, EV, 52-week range, forward P/E | Alpha Vantage 2026-07-29 |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-29 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-29 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-07-29 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-07-29 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-07-29 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-07-29 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-07-29 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-07-29 | Segment revenue, margins, multiples, AI decomposition | company_context (authored, tagged) |
| MCH qualitative analysis | inference | 2026-07-29 | Moat, regulatory risk, scenario macro, catalysts | company_context enrichment (authored) |
| MCH investment thesis & falsification triggers | house estimate | 2026-07-29 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- This report is produced by the MCH Advisory quantitative research engine — valuation, scenarios, Monte Carlo and the decision layer are generated systematically from the disclosed inputs and the archetype/industry driver sets, and reviewed rather than written name-by-name. Every figure reconciles to the appendix and every score exposes its inputs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.